Alendronate may protect against increased periodontitis-related bone loss in estrogen-deficient rats

Journal of Periodontology

Volumn 75, Issue 9, 2004, Pages 1196-1202

  Mendes Duarte, Poliana ^a   de Assis, Daniel Roberto ^a   Casati, Marcio Zaffalon ^a   Sallum, Antonio Wilson ^a   Sallum, Enilson Antonio ^a   Nociti Jr , Francisco H ^a,b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b NONE   (Brazil)

Author keywords

Alendronate therapeutic use; Alveolar bone loss therapy; Animal studies; Estradiol therapeutic use; Estrogen deficiency

Indexed keywords

ALENDRONIC ACID; ESTRADIOL; ESTROGEN;

ALVEOLAR BONE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; LIGATION; MANDIBLE; MOLAR TOOTH; NONHUMAN; OSTEOLYSIS; OVARIECTOMY; PERIODONTITIS; RAT; RAT STRAIN; STATISTICAL ANALYSIS; TOOTH PLAQUE;

ALENDRONATE; ALKALINE PHOSPHATASE; ALVEOLAR BONE LOSS; ALVEOLAR PROCESS; ANIMALS; DENTAL PLAQUE INDEX; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; FURCATION DEFECTS; OVARIECTOMY; PERIODONTITIS; RANDOM ALLOCATION; RATS; RATS, WISTAR; TIME FACTORS;

EID: 7044264638     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2004.75.9.1196     Document Type: Article

References (43)

1. Page RC, Schroeder HE. Pathogenesis of inflammatory periodontal disease. A summary of current work. Lab Invest 1976;34:235-249.
2. Genco RJ. Current view of risk factors for periodontal disease. J Periodontol 1996;67(Suppl.): 1041-1049.
3. Grossi SG, Genco RJ, Machtei EE, et al. Assessment of risk for periodontal disease. II. Risk indicators for alveolar bone loss. J Periodontol 1995;66:23-29.
4. Harrison JE. Osteoporosis. In: Tam CS, Heersche JNM, Murray TM, eds. Metabolic Bone Diseases: Cellular and Tissue Mechanisms. Boca Raton, FL: CRC Press; 1989:240-267.
5. Eriksen EF, Colvard DS, Berg NJ, et al. Evidence of estrogen receptors in normal human osteoblast-like cells. Science 1988;241:84-86.
6. Oursler MJ. Estrogen regulation of gene expression in osteoblasts and osteoclasts. Crit Rev Eukaryot Gene Expr 1998;8:125-140.
7. Lindberg MK, Erlandsson M, Alatalo SL, et al. Estrogen receptor alpha, but not estrogen receptor beta, is involved in the regulation of the OPG/RANKL (osteoprotegerin/ receptor activator of NF-kappa B ligand) ratio and serum interleukin-6 in male mice. J Endocrinol 2001;171:425-433.
8. Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998;139:1329-1337.
9. Pacifici R. Is there a causal role for IL-1 in postmenopausal bone loss? Calcif Tissue Int 1992;50:295-299.
10. Girasole G, Passeri G, Pedrazzoni M, Giuliani N, Passeri M. Interleukin-6: A pathogenetic role in the postmenopausal osteoporosis? Acta Biomed Ateneo Parmense 1995;66: 125-138.
11. Kribbs PJ, Chesnut CH 3rd, Ott SM, Kilcoyne RF. Relationships between mandibular and skeletal bone in an osteoporotic population. J Prosthet Dent 1989;62:703-707.
12. Kribbs PJ. Comparison of mandibular bone in normal and osteoporotic women. J Prosthet Dent 1990;63:218-222.
13. von Wowern N, Klausen B, Kollerup G. Osteoporosis: A risk factor in periodontal disease. J Periodontol 1994;65: 1134-1138.
14. Wactawski-Wende J, Grossi SG, Trevisan M, et al. The role of osteopenia in oral bone loss and periodontal disease. J Periodontol 1996;67:1076-1084.
15. Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science 2000;289:1508-1518.
16. Buffo L, Rossini M, Buoncristiano A, et al. Diphosphonates: An alternative to estrogen therapy in postmenopausal osteoporosis. Experience with alendronate. Minerva Ginecol 1996;48:263-272.
17. Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Sandora AC II. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 1996;101:488-501.
18. Seedor JG, Quartucci HA, Thompson DD. The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats. J Bone Miner Res 1991;6:339-346.
19. Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclastos in vitro and in vivo. J Bone Miner Res 1995;10:1478-1487.
20. Rodan GA. Mechanisms of action of bisphosphonates. Annu Rev Pharmacol Toxicol 1998;38:375-388.
21. Wronski TJ, Dann LM, Qi H, Yen C-F. Skeletal effects of withdrawal of estrogen and diphosphonate treatment in ovariectomized rats. Calcif Tissue Int 1993;53:210-216.
22. Rossini M, Gatti D, Zamberlan N, Braga V, Dorrizi R, Adami S. Long-term effect of treatment course with oral alendronate of postmenopausal osteoporosis. J Bone Miner Res 1994;11:1833-1837.
23. Wronski TJ, Yen C-F, Scott KS. Estrogen and diphosphonate treatment provide long-term protection against osteopenia in ovariectomized rats. J Bone Miner Res 1991;6: 387-394.
24. Reginster JY, Lecart MP, Deraisy R, et al. Prevention of postmenopausal bone loss by tiludronato. Lancet 1981; 459-461.
25. Duarte PM, Gonçalves PF, Sallum AW, Sallum EA, Casati MZ, Nociti FH. Effect of an estrogen- deficient state and its therapy on bone loss resulting from an experimental periodontitis in rats. J Periodontal Res 2004;39:107-110.
26. Wronski TJ, Schenck PA, Cintron M, Walsh CC. Effect of body weight on osteopenia in ovariectomized rats. Calcif Tissue Int 1987;40:155-159.
27. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-319.
28. Takayanagi H, Kim S, Matsuo K, et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β. Nature 2002;416:744-749.
29. Teng Y-TA, Nguyen H, Gao X, et al. Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J Clin Invest 2000;106:R59-R67.
30. Oshiro T, Shiotani A, Shibasaki Y, Sasaki T. Osteoclast induction in periodontal tissue during experimental movement of incisors in osteoprotegerin-deficient mice. Anat Rec 2002;266:218-225.
31. 2 synthesis. J Bone Miner Res 2002; 17:210-220.
32. Tanaka M, Ejiri S, Toyoka E, Kohno S, Ozawa H. Effects of ovariectomy on trabecular structures of rats alveolar bone. J Periodontal Res 2002;37:161-165.
33. Kawamoto S, Ejiri S, Nagaoka E, Ozawa H. Effect of oestrogen deficiency on osteoclastogenesis in the rat periodontium. Arch Oral Biol 2002;47:67-73.
34. Hidaka S, Okamoto Y, Yamada Y, Miyazaki K, Kimura T. Alterations in the periodontium after ovariectomy in rats: The effects of a Japanese herbal medicine, Chujo-to. Phytother Res 2000;14:527-533.
35. Thompson DD, Seedor JG, Quartuccio H, et al. The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboons. J Bone Miner Res 1992;7:951-960.
36. Fleisch H. Experimental basis for the use of bisphosphonates in Paget's disease of bone. Clin Orthop 1987;217: 72-78.
37. Schenk R, Eggli P, Felix R, Fleisch H, Rossini S. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int 1986;38:342-349.
38. Yaffe A, Fine N, Alt 1, Binderman 1. The effect of bisphosphonate on alveolar bone resorption following mucoperiosteal flap surgery in the mandible of rat. J Periodontol 1995;66:999-1003.
39. Huges DE, Mian M, Guillard-Cumming DF, Russel RGG. The cellular mechanism of action of bisphosphonates. Drugs Exp Clin Res 1991;17:109-114.
40. Lerner UH, Larsson A. Effect of four bisphosphonates on bone resorption, lysosomal enzyme release, protein synthesis and mitotic activity in mouse calvarial bones in vitro.Bone 1987;8:179-189.
41. Reddy MS, Weatherford TW, Smith CA, et al. Alendronate treatment of naturally-occurring periodontitis in beagle dogs. J Periodontol 1995;66:211-217.
42. Brunsvold MA, Chaves ES, Kornman KS, Aufdemorte TB, Wood R. Effects of a bisphosphonate on experimental periodontitis in monkeys. J Periodontol 1992;63:825-830.
43. Fleisch MH. Bisphosphonates - history and experimental basis. Bone 1987;8(Suppl. 1):S23-S28.